Charles River can support your monoclonal antibody research with our expertise in the initial stages of safety assessment for therapeutic antibodies targeted for use in humans. We hold a full range of tissues from various animal species, including human.
For immunohistochemistry-based tissue cross-reactivity studies, we provide efficiency of scale in full compliance with Good Laboratory Practice (GLP) regulations and interpretation of findings, and can represent you in presenting to the applicable regulatory agencies.
We provide correlative studies that are designed as an adjunct to clinical trials. These studies assist in determining whether a drug is reaching the intended target and whether the drug will work the same way in humans as it has in animals. Because each project has its own unique requirements, our pathologists and scientists will work closely with you to identify which tissue-based biomarkers to assess.